{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:03:54Z","timestamp":1762481034633,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:00Z","timestamp":1694822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.gore.2023.101278","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T18:15:36Z","timestamp":1695665736000},"page":"101278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Digging into phenotype change in mismatch repair deficient endometrial carcinoma and treatment with immune checkpoint inhibition, a case report"],"prefix":"10.1016","volume":"49","author":[{"given":"Macarena","family":"Rey-C\u00e1rdenas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Parrilla-Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Manso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Sanchez-Bayona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Alvarez-Conejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-9762","authenticated-orcid":false,"given":"Ainhoa","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.gore.2023.101278_b0005","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/cncr.34025","article-title":"A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability","volume":"128","author":"Bellone","year":"2022","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.gore.2023.101278_b0010","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynecol. Obst."},{"issue":"1","key":"10.1016\/j.gore.2023.101278_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","author":"Bonneville","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.gore.2023.101278_b0020","article-title":"MLH1 hypermethylation predicts por outcomes with pembrolizumab in recurrent endometrial cancer","author":"Borden","year":"2022","journal-title":"Soc. Gynecol. Oncol. (SGO)"},{"issue":"5","key":"10.1016\/j.gore.2023.101278_b0025","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1586\/14737159.2016.1156533","article-title":"Mismatch repair deficiency testing in clinical practice","volume":"16","author":"Buza","year":"2016","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"1","key":"10.1016\/j.gore.2023.101278_b0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-021-00301-z","article-title":"Immunotherapy in endometrial cancer: rationale, practice and perspectives","volume":"9","author":"Cao","year":"2021","journal-title":"Biomark Res."},{"issue":"1","key":"10.1016\/j.gore.2023.101278_b0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2023.101278_b0040","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.gore.2023.101278_b0045","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.3802\/jgo.2021.32.e79","article-title":"MLH1 promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial carcinomas","volume":"32","author":"Kaneko","year":"2021","journal-title":"J. Gynecol. Oncol."},{"issue":"6349","key":"10.1016\/j.gore.2023.101278_b0050","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"29","key":"10.1016\/j.gore.2023.101278_b0055","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.gore.2023.101278_b0060","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.gore.2023.101278_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"52","key":"10.1016\/j.gore.2023.101278_b0070","doi-asserted-by":"crossref","first-page":"90532","DOI":"10.18632\/oncotarget.20042","article-title":"Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity","volume":"8","author":"Mittica","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.gore.2023.101278_b0075","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: A nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.gore.2023.101278_b0080","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann. Oncol."},{"doi-asserted-by":"crossref","unstructured":"Spinosa D, Wong J, Whitaker R. To test or re-test, that is the question: Comparison of the mismatch repair deficiency between primary and metastatic sites of uterine cancers. Abstract presented at: SGO 2022; 2022 Mar 18.","key":"10.1016\/j.gore.2023.101278_b0085","DOI":"10.1016\/S0090-8258(22)01313-0"},{"issue":"3","key":"10.1016\/j.gore.2023.101278_b0090","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.gore.2023.101278_b0095","article-title":"Post hoc analysis of objective response rate by mismatch repair protein dimer loss\/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab","author":"Tinker","year":"2022","journal-title":"Int. Gynecol. Cancer Soc. (IGCS)"},{"unstructured":"Tinker A. Progression-free survival and overall survival in advanced\/recurrent mismatch repair deficient\/microsatellite instability\u2013high or proficient\/stable endometrial cancer treated with dostarlimab in the GARNET study. Poster presented at: 2022 European Society for Medical Oncology Congress; 2022 Sep 9; Paris, France.","key":"10.1016\/j.gore.2023.101278_b0100"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923002953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923002953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:58:52Z","timestamp":1762480732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578923002953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":20,"alternative-id":["S2352578923002953"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2023.101278","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Digging into phenotype change in mismatch repair deficient endometrial carcinoma and treatment with immune checkpoint inhibition, a case report","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2023.101278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101278"}}